Join to View Full Profile
650 W 168th StBb-1427 Dept Pathology Columbia UniversityNew York, NY 10032
Phone+1 212-305-0395
Fax+1 212-305-5498
Are you Dr. Lauring?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Brett Lauring, MD is a board certified pathologist in New York, New York. He is currently licensed to practice medicine in New York.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Pathology-Anatomic and Clinical, 1996 - 2001
New York University School of MedicineClass of 1996
Certifications & Licensure
NY State Medical License 1997 - 2021
American Board of Pathology Anatomic Pathology
Publications & Presentations
PubMed
- 38 citationsSafety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.Linong Ji, Yanmei Liu, Heng Miao, Yongli Xie, Ming Yang
Diabetes, Obesity & Metabolism. 2019-06-01 - 46 citationsLong-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.Silvina Gallo, Bernard Charbonnel, Allison Goldman, Harry Shi, Susan Huyck
Diabetes, Obesity & Metabolism. 2019-04-01 - 28 citationsResults of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus i...Priscilla Hollander, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory T. Golm
Current Medical Research and Opinion. 2019-03-25
Press Mentions
Kallyope Inc. Appoints Brett Lauring as Chief Medical OfficerFebruary 5th, 2019
Kallyope Enters Phase 2 with First-in-Class Oral Approach for the Treatment of Both Obesity and Type 2 DiabetesSeptember 28th, 2023- Kallyope to Expand Its Metabolic Disorder Programme GloballyOctober 26th, 2023
